Buy Rating for Disc Medicine Driven by Promising Bitopertin Prospects and Strategic Advancements

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Disc Medicine (IRON – Research Report), retaining the price target of $118.00.

Douglas Tsao’s rating is based on several compelling factors surrounding Disc Medicine’s prospects. The company’s lead candidate, bitopertin, is on track for an accelerated approval pathway for the treatment of erythropoietic protoporphyria (EPP), supported by positive results from the BEACON and AURORA studies. These studies demonstrated significant reductions in protoporphyrin IX (PPIX), a surrogate endpoint, which is crucial given the unmet needs of EPP patients and the limited efficacy of the only FDA-approved treatment, Scenesse.
Additionally, Disc Medicine has achieved alignment with the FDA on the manufacturing aspects of the bitopertin NDA package, and a Pre-NDA meeting is scheduled to finalize the submission format and content. The initiation of the APOLLO confirmatory trial further strengthens the potential for bitopertin’s full approval, with data expected in late 2026. These strategic advancements and the anticipated regulatory milestones underpin Tsao’s confidence in Disc Medicine’s stock, leading to the Buy rating.

In another report released today, BMO Capital also maintained a Buy rating on the stock with a $112.00 price target.